Bradley Dixon
Concepts (257)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glomerulonephritis, Membranoproliferative | 6 | 2026 | 29 | 2.710 |
Why?
| | Complement C3 | 5 | 2026 | 195 | 2.210 |
Why?
| | Atypical Hemolytic Uremic Syndrome | 8 | 2024 | 23 | 2.130 |
Why?
| | Kidney Diseases | 6 | 2025 | 428 | 1.190 |
Why?
| | Thrombotic Microangiopathies | 6 | 2020 | 19 | 1.060 |
Why?
| | Immune Complex Diseases | 1 | 2026 | 6 | 0.960 |
Why?
| | Antigen-Antibody Complex | 1 | 2026 | 70 | 0.940 |
Why?
| | Renal Insufficiency, Chronic | 6 | 2026 | 640 | 0.810 |
Why?
| | Complement Inactivating Agents | 5 | 2026 | 78 | 0.720 |
Why?
| | Kidney | 11 | 2026 | 1498 | 0.700 |
Why?
| | Antibodies, Monoclonal, Humanized | 9 | 2024 | 992 | 0.680 |
Why?
| | Tuberous Sclerosis | 4 | 2017 | 56 | 0.620 |
Why?
| | TRPM Cation Channels | 2 | 2019 | 74 | 0.610 |
Why?
| | Proteinuria | 5 | 2026 | 103 | 0.600 |
Why?
| | Hypertension | 5 | 2026 | 1272 | 0.590 |
Why?
| | Hemolytic-Uremic Syndrome | 1 | 2019 | 15 | 0.570 |
Why?
| | Nephrotic Syndrome | 3 | 2025 | 44 | 0.570 |
Why?
| | Hematopoietic Stem Cell Transplantation | 5 | 2019 | 704 | 0.570 |
Why?
| | Lupus Nephritis | 3 | 2025 | 67 | 0.570 |
Why?
| | Complement System Proteins | 5 | 2025 | 326 | 0.520 |
Why?
| | Antihypertensive Agents | 3 | 2026 | 519 | 0.520 |
Why?
| | Acute Kidney Injury | 5 | 2025 | 866 | 0.520 |
Why?
| | Osmoregulation | 1 | 2017 | 4 | 0.500 |
Why?
| | DNA Damage | 2 | 2011 | 439 | 0.500 |
Why?
| | Kidney Tubules, Collecting | 1 | 2017 | 25 | 0.500 |
Why?
| | Osmotic Pressure | 1 | 2017 | 41 | 0.500 |
Why?
| | Immunosuppressive Agents | 6 | 2025 | 829 | 0.480 |
Why?
| | Kidney Transplantation | 5 | 2026 | 735 | 0.440 |
Why?
| | Autoimmunity | 1 | 2020 | 925 | 0.410 |
Why?
| | Peptides, Cyclic | 2 | 2026 | 276 | 0.410 |
Why?
| | Autoantibodies | 2 | 2020 | 1500 | 0.390 |
Why?
| | Child | 26 | 2026 | 22693 | 0.340 |
Why?
| | Epithelial Cells | 2 | 2019 | 1119 | 0.340 |
Why?
| | Cell Line | 3 | 2019 | 2814 | 0.330 |
Why?
| | Urothelium | 1 | 2011 | 33 | 0.330 |
Why?
| | Angiotensin Receptor Antagonists | 2 | 2026 | 115 | 0.320 |
Why?
| | Renal Dialysis | 3 | 2026 | 461 | 0.320 |
Why?
| | Adolescent | 18 | 2026 | 22557 | 0.310 |
Why?
| | Humans | 48 | 2026 | 146342 | 0.310 |
Why?
| | Osmolar Concentration | 1 | 2009 | 165 | 0.290 |
Why?
| | Glomerular Filtration Rate | 4 | 2026 | 745 | 0.280 |
Why?
| | Pyrimidines | 3 | 2022 | 532 | 0.280 |
Why?
| | RecQ Helicases | 1 | 2008 | 9 | 0.280 |
Why?
| | Angiomyolipoma | 3 | 2014 | 21 | 0.280 |
Why?
| | Cell Cycle | 1 | 2011 | 595 | 0.260 |
Why?
| | Biopsy | 3 | 2026 | 1075 | 0.260 |
Why?
| | Complement Activation | 3 | 2025 | 412 | 0.250 |
Why?
| | Purines | 1 | 2008 | 188 | 0.250 |
Why?
| | Urinary Bladder | 1 | 2009 | 194 | 0.250 |
Why?
| | Child, Preschool | 12 | 2026 | 11913 | 0.250 |
Why?
| | Treatment Outcome | 11 | 2026 | 11821 | 0.240 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 2 | 2026 | 228 | 0.240 |
Why?
| | Escherichia coli Proteins | 1 | 2008 | 200 | 0.240 |
Why?
| | Benzoates | 1 | 2026 | 48 | 0.240 |
Why?
| | Risk Factors | 6 | 2026 | 10921 | 0.230 |
Why?
| | Nephrology | 2 | 2024 | 59 | 0.230 |
Why?
| | Induction Chemotherapy | 1 | 2025 | 87 | 0.220 |
Why?
| | Prenatal Injuries | 1 | 2005 | 1 | 0.220 |
Why?
| | Hypertension, Renal | 1 | 2005 | 15 | 0.220 |
Why?
| | Calcium Channel Blockers | 1 | 2026 | 165 | 0.220 |
Why?
| | Retroperitoneal Space | 1 | 2005 | 19 | 0.220 |
Why?
| | Nephrocalcinosis | 1 | 2024 | 12 | 0.210 |
Why?
| | Familial Hypophosphatemic Rickets | 1 | 2024 | 6 | 0.210 |
Why?
| | Hematoma | 1 | 2005 | 62 | 0.210 |
Why?
| | Male | 22 | 2026 | 73396 | 0.210 |
Why?
| | Piperidines | 1 | 2026 | 225 | 0.210 |
Why?
| | Kidney Diseases, Cystic | 2 | 2017 | 24 | 0.210 |
Why?
| | Rituximab | 1 | 2025 | 208 | 0.210 |
Why?
| | Glomerulosclerosis, Focal Segmental | 1 | 2024 | 43 | 0.200 |
Why?
| | Female | 23 | 2026 | 79499 | 0.200 |
Why?
| | Polycystic Kidney Diseases | 1 | 2005 | 82 | 0.200 |
Why?
| | Cost of Illness | 1 | 2026 | 323 | 0.200 |
Why?
| | Kidney Neoplasms | 3 | 2014 | 419 | 0.200 |
Why?
| | Lymphohistiocytosis, Hemophagocytic | 2 | 2017 | 33 | 0.200 |
Why?
| | Disease Management | 2 | 2020 | 651 | 0.200 |
Why?
| | Nephritis | 1 | 2023 | 22 | 0.190 |
Why?
| | Disease Progression | 3 | 2026 | 2867 | 0.190 |
Why?
| | Slipped Capital Femoral Epiphyses | 1 | 2022 | 10 | 0.190 |
Why?
| | Femur Head Necrosis | 1 | 2022 | 17 | 0.180 |
Why?
| | Delphi Technique | 1 | 2024 | 350 | 0.180 |
Why?
| | Algorithms | 3 | 2026 | 1849 | 0.180 |
Why?
| | Terminology as Topic | 1 | 2024 | 253 | 0.180 |
Why?
| | Complement Factor B | 1 | 2023 | 106 | 0.180 |
Why?
| | Self-Management | 1 | 2025 | 207 | 0.180 |
Why?
| | Indoles | 1 | 2026 | 511 | 0.180 |
Why?
| | Pharmacists | 1 | 2025 | 260 | 0.180 |
Why?
| | Arthritis, Juvenile | 1 | 2022 | 64 | 0.180 |
Why?
| | Wounds, Nonpenetrating | 1 | 2005 | 305 | 0.170 |
Why?
| | DNA | 1 | 2008 | 1421 | 0.170 |
Why?
| | Rheumatology | 1 | 2022 | 136 | 0.160 |
Why?
| | Recurrence | 1 | 2024 | 1133 | 0.160 |
Why?
| | Phenotype | 2 | 2026 | 3206 | 0.150 |
Why?
| | Glomerulonephritis | 1 | 2019 | 46 | 0.150 |
Why?
| | Tumor Suppressor Proteins | 2 | 2012 | 315 | 0.140 |
Why?
| | Plasma Exchange | 1 | 2019 | 18 | 0.140 |
Why?
| | Cilia | 2 | 2019 | 171 | 0.140 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2021 | 241 | 0.140 |
Why?
| | Mice, Transgenic | 2 | 2017 | 2134 | 0.140 |
Why?
| | Hirschsprung Disease | 1 | 2020 | 93 | 0.140 |
Why?
| | Disease Susceptibility | 1 | 2020 | 339 | 0.140 |
Why?
| | TRPP Cation Channels | 1 | 2019 | 76 | 0.140 |
Why?
| | Plasmapheresis | 1 | 2018 | 24 | 0.140 |
Why?
| | Critical Illness | 2 | 2023 | 908 | 0.140 |
Why?
| | Electronic Health Records | 3 | 2023 | 1210 | 0.140 |
Why?
| | Escherichia coli Infections | 1 | 2019 | 125 | 0.130 |
Why?
| | Renal Replacement Therapy | 1 | 2019 | 102 | 0.130 |
Why?
| | Sirolimus | 2 | 2017 | 282 | 0.130 |
Why?
| | Creatinine | 3 | 2026 | 511 | 0.130 |
Why?
| | Fluid Therapy | 1 | 2019 | 154 | 0.130 |
Why?
| | Blood Component Transfusion | 1 | 2018 | 99 | 0.130 |
Why?
| | Hydroxyprostaglandin Dehydrogenases | 1 | 2017 | 3 | 0.130 |
Why?
| | GABA Plasma Membrane Transport Proteins | 1 | 2017 | 7 | 0.130 |
Why?
| | Caregivers | 2 | 2026 | 1080 | 0.130 |
Why?
| | Transfection | 2 | 2017 | 916 | 0.120 |
Why?
| | Saline Solution, Hypertonic | 1 | 2017 | 43 | 0.120 |
Why?
| | TRPV Cation Channels | 1 | 2017 | 43 | 0.120 |
Why?
| | Erythrocyte Transfusion | 1 | 2019 | 226 | 0.120 |
Why?
| | Quality of Life | 2 | 2026 | 3200 | 0.120 |
Why?
| | Plasma | 1 | 2018 | 222 | 0.120 |
Why?
| | Time Factors | 2 | 2026 | 7109 | 0.120 |
Why?
| | Autoimmune Diseases | 1 | 2020 | 467 | 0.120 |
Why?
| | Streptococcal Infections | 1 | 2019 | 179 | 0.120 |
Why?
| | Gene Editing | 1 | 2017 | 89 | 0.110 |
Why?
| | Infant | 7 | 2025 | 10114 | 0.110 |
Why?
| | Patient Selection | 1 | 2019 | 728 | 0.110 |
Why?
| | CRISPR-Cas Systems | 1 | 2017 | 163 | 0.110 |
Why?
| | Cytomegalovirus Infections | 1 | 2017 | 206 | 0.110 |
Why?
| | Young Adult | 7 | 2026 | 14330 | 0.110 |
Why?
| | Diagnosis, Differential | 1 | 2019 | 1503 | 0.100 |
Why?
| | Transplantation Conditioning | 1 | 2015 | 193 | 0.100 |
Why?
| | Pericytes | 1 | 2014 | 42 | 0.100 |
Why?
| | Complement Membrane Attack Complex | 1 | 2013 | 38 | 0.100 |
Why?
| | Retrospective Studies | 7 | 2025 | 17438 | 0.100 |
Why?
| | Adult | 7 | 2026 | 41087 | 0.100 |
Why?
| | Complement Factor D | 2 | 2022 | 28 | 0.090 |
Why?
| | Transplantation, Autologous | 2 | 2013 | 306 | 0.090 |
Why?
| | Complement Pathway, Alternative | 1 | 2013 | 123 | 0.090 |
Why?
| | Indazoles | 2 | 2022 | 86 | 0.090 |
Why?
| | Proline | 2 | 2022 | 79 | 0.090 |
Why?
| | Aminopyridines | 2 | 2022 | 128 | 0.090 |
Why?
| | Hematologic Neoplasms | 1 | 2013 | 170 | 0.090 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2012 | 120 | 0.080 |
Why?
| | Antigens, Polyomavirus Transforming | 1 | 2011 | 15 | 0.080 |
Why?
| | Biomarkers | 4 | 2025 | 4340 | 0.080 |
Why?
| | Nephrolithiasis | 1 | 2010 | 10 | 0.080 |
Why?
| | Double-Blind Method | 2 | 2026 | 2070 | 0.080 |
Why?
| | Histoplasmosis | 1 | 2010 | 15 | 0.080 |
Why?
| | Prognosis | 1 | 2019 | 4351 | 0.080 |
Why?
| | Mice | 3 | 2019 | 18297 | 0.070 |
Why?
| | DNA Breaks, Double-Stranded | 1 | 2009 | 55 | 0.070 |
Why?
| | Organ Specificity | 1 | 2009 | 307 | 0.070 |
Why?
| | Kanamycin Resistance | 1 | 2008 | 2 | 0.070 |
Why?
| | Cell Line, Tumor | 3 | 2014 | 3545 | 0.070 |
Why?
| | Viral Regulatory and Accessory Proteins | 1 | 2008 | 27 | 0.070 |
Why?
| | Prospective Studies | 4 | 2023 | 8123 | 0.070 |
Why?
| | Mutation | 2 | 2010 | 4093 | 0.070 |
Why?
| | Endothelium, Vascular | 1 | 2014 | 952 | 0.070 |
Why?
| | Renal Insufficiency | 1 | 2010 | 173 | 0.070 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2011 | 259 | 0.070 |
Why?
| | Incidence | 1 | 2014 | 2936 | 0.060 |
Why?
| | Stomach Neoplasms | 1 | 2009 | 128 | 0.060 |
Why?
| | Blood Pressure | 2 | 2025 | 1765 | 0.060 |
Why?
| | United States | 4 | 2025 | 16136 | 0.060 |
Why?
| | Stress, Mechanical | 1 | 2009 | 497 | 0.060 |
Why?
| | Plasmids | 1 | 2008 | 373 | 0.060 |
Why?
| | Colonic Neoplasms | 1 | 2009 | 259 | 0.060 |
Why?
| | DNA Repair | 1 | 2009 | 255 | 0.060 |
Why?
| | DNA, Bacterial | 1 | 2008 | 319 | 0.060 |
Why?
| | DNA Replication | 1 | 2008 | 248 | 0.060 |
Why?
| | Signal Transduction | 2 | 2017 | 5246 | 0.060 |
Why?
| | Blotting, Western | 1 | 2008 | 1177 | 0.060 |
Why?
| | Mice, Inbred C57BL | 1 | 2017 | 6034 | 0.060 |
Why?
| | Antigens, CD20 | 1 | 2025 | 34 | 0.060 |
Why?
| | Mycophenolic Acid | 1 | 2025 | 117 | 0.050 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2025 | 116 | 0.050 |
Why?
| | Cyclophosphamide | 1 | 2025 | 275 | 0.050 |
Why?
| | Kidney Glomerulus | 1 | 2025 | 129 | 0.050 |
Why?
| | Nucleic Acid Conformation | 1 | 2008 | 724 | 0.050 |
Why?
| | Comparative Effectiveness Research | 1 | 2026 | 171 | 0.050 |
Why?
| | Repressor Proteins | 1 | 2008 | 430 | 0.050 |
Why?
| | Apoptosis | 2 | 2012 | 2439 | 0.050 |
Why?
| | Escherichia coli | 1 | 2008 | 832 | 0.050 |
Why?
| | Animals | 3 | 2019 | 38107 | 0.050 |
Why?
| | Remission Induction | 1 | 2024 | 308 | 0.050 |
Why?
| | Adrenal Cortex Hormones | 1 | 2025 | 486 | 0.050 |
Why?
| | Consensus | 1 | 2024 | 467 | 0.050 |
Why?
| | Middle Aged | 4 | 2025 | 36619 | 0.040 |
Why?
| | Atrophy | 1 | 2022 | 199 | 0.040 |
Why?
| | Immunoglobulin A | 1 | 2023 | 205 | 0.040 |
Why?
| | Graft Survival | 1 | 2024 | 523 | 0.040 |
Why?
| | Complement C5 | 1 | 2020 | 33 | 0.040 |
Why?
| | Predictive Value of Tests | 1 | 2025 | 2113 | 0.040 |
Why?
| | Radiography | 1 | 2022 | 861 | 0.040 |
Why?
| | Fibrosis | 1 | 2022 | 568 | 0.040 |
Why?
| | Forms and Records Control | 1 | 2019 | 21 | 0.040 |
Why?
| | Information Services | 1 | 2019 | 42 | 0.040 |
Why?
| | Pregnenolone | 1 | 2019 | 3 | 0.040 |
Why?
| | Gelatinases | 1 | 2019 | 6 | 0.040 |
Why?
| | Observational Studies as Topic | 1 | 2019 | 133 | 0.040 |
Why?
| | Fibrinogen | 1 | 2020 | 182 | 0.040 |
Why?
| | Area Under Curve | 1 | 2019 | 335 | 0.040 |
Why?
| | Cystatin C | 1 | 2019 | 65 | 0.040 |
Why?
| | Single-Blind Method | 1 | 2019 | 313 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 2 | 2017 | 3926 | 0.040 |
Why?
| | International Classification of Diseases | 1 | 2019 | 142 | 0.040 |
Why?
| | Gene Knockout Techniques | 1 | 2019 | 122 | 0.030 |
Why?
| | Flavonoids | 1 | 2019 | 85 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2025 | 1763 | 0.030 |
Why?
| | Severity of Illness Index | 2 | 2019 | 2921 | 0.030 |
Why?
| | Allografts | 1 | 2019 | 151 | 0.030 |
Why?
| | ROC Curve | 1 | 2019 | 617 | 0.030 |
Why?
| | Calcium Signaling | 1 | 2019 | 246 | 0.030 |
Why?
| | Kidney Function Tests | 1 | 2017 | 156 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2024 | 3017 | 0.030 |
Why?
| | Hospitals, Pediatric | 1 | 2019 | 561 | 0.030 |
Why?
| | Metabolic Clearance Rate | 1 | 2015 | 115 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2021 | 925 | 0.030 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2014 | 25 | 0.030 |
Why?
| | Valsartan | 1 | 2014 | 33 | 0.030 |
Why?
| | Complement Hemolytic Activity Assay | 1 | 2013 | 2 | 0.030 |
Why?
| | Tetrazoles | 1 | 2014 | 50 | 0.030 |
Why?
| | Valine | 1 | 2014 | 84 | 0.030 |
Why?
| | Drug Dosage Calculations | 1 | 2013 | 27 | 0.030 |
Why?
| | Renin-Angiotensin System | 1 | 2014 | 80 | 0.020 |
Why?
| | Angiotensin II | 1 | 2014 | 102 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2026 | 6073 | 0.020 |
Why?
| | Veterans | 1 | 2025 | 1650 | 0.020 |
Why?
| | Leupeptins | 1 | 2012 | 13 | 0.020 |
Why?
| | Transplantation, Homologous | 1 | 2013 | 416 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2014 | 1041 | 0.020 |
Why?
| | Proteasome Inhibitors | 1 | 2012 | 42 | 0.020 |
Why?
| | Eukaryotic Initiation Factor-2 | 1 | 2012 | 34 | 0.020 |
Why?
| | Transcription Factor CHOP | 1 | 2012 | 32 | 0.020 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2012 | 88 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2023 | 5899 | 0.020 |
Why?
| | Everolimus | 1 | 2012 | 112 | 0.020 |
Why?
| | Pregnancy | 1 | 2005 | 7230 | 0.020 |
Why?
| | Gene Deletion | 1 | 2013 | 385 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2013 | 790 | 0.020 |
Why?
| | Cohort Studies | 1 | 2022 | 6077 | 0.020 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2012 | 141 | 0.020 |
Why?
| | Caspase 3 | 1 | 2012 | 240 | 0.020 |
Why?
| | Multiprotein Complexes | 1 | 2012 | 168 | 0.020 |
Why?
| | Survival Analysis | 1 | 2013 | 1378 | 0.020 |
Why?
| | Drug Monitoring | 1 | 2013 | 399 | 0.020 |
Why?
| | False Negative Reactions | 1 | 2010 | 61 | 0.020 |
Why?
| | Obesity | 1 | 2023 | 3131 | 0.020 |
Why?
| | Antifungal Agents | 1 | 2010 | 153 | 0.020 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2012 | 455 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2020 | 6460 | 0.020 |
Why?
| | Genotype | 1 | 2013 | 1879 | 0.020 |
Why?
| | Calcium | 1 | 2014 | 1181 | 0.020 |
Why?
| | Phosphorylation | 1 | 2012 | 1724 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2014 | 2502 | 0.020 |
Why?
| | Proteins | 1 | 2012 | 1022 | 0.010 |
Why?
| | Aged | 1 | 2025 | 26432 | 0.010 |
Why?
| | Antineoplastic Agents | 1 | 2012 | 2219 | 0.010 |
Why?
|
|
Dixon's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|